The vaccine jointly developed by Pfizer and BioNTech was 90 percent effective in preventing Covid-19 infections in ongoing Phase 3 trials. This has been announced by the companies on Monday. Globally, over 50 million have now been hit by the Covid-19. Protection in patients was achieved seven days after the second of two doses, and 28 days after the first, according to preliminary findings.